FreeCME

Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction

This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

Grantors:

Bristol-Myers Squibb
AstraZeneca, LP

Release date: May 6, 2016

Valid through: May 6, 2017

Specialty: Immunology, Oncology

Media: Internet

Estimated Time to Complete Activity: 1.5 hours (95 min)

CME Provider contact information: To contact CME provider, call 214 820 2317

Target Audience

This Internet enduring material is directed primarily to hematologists/oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in immunotherapy options for selected tumor types. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Statement of Need / Program Overview

This Internet enduring material is intended to improve care of patients with immunotherapeutic options for selected tumor types by accelerating adoption of new evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

This program consists of 5 continuing education activities.

Click the links below to review the activity launch pages containing full disclosure information.

Module 1

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the mechanisms of action of checkpoint inhibitors and their impact on novel therapies in cancer
  • Identify current strategies in immunotherapy combination with molecular therapies in cancer
  • Evaluate and implement immunotherapy options for malignant melanoma

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 1

Module 2

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify current strategies in treatment of non-small-cell lung cancer utilizing immune checkpoint pathway inhibitors
  • Identify currently accruing immunotherapy options for head & neck cancer
  • Identify patterns of response with emerging immunotherapy options for hematological malignancies

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 2

Module 3

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the emerging immunotherapeutic approaches for renal cell carcinoma
  • Describe emerging immunotherapeutic approaches for bladder cancer
  • Identify currently accruing immunotherapy options for prostate cancer

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 3

Module 4

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select immunotherapy options for hepatic and gastrointestinal cancers
  • Identify the role of neoantigens in the immunotherapy options for ovarian cancer
  • Increase the awareness of currently accruing immunotherapy modality combination clinical trials across tumor types

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 4

Module 5

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of prognostic and predictive biomarkers in the immunotherapeutic approaches
  • Evaluate the unique toxicity issues with immunotherapy options across tumor types

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Start Module 5